Health - Minutes of Evidence [Back to Report]
Here you can browse the Minutes of Evidence which were ordered by the House of Commons to be printed 13 January 2000.
THURSDAY 13 JANUARY 2000
Members present:
Mr David Hinchliffe, in the Chair
Mr David Amess | Mr John Gunnell
|
Mr John Austin | Mr Stephen Hesford
|
Dr Peter Brand | Dr Howard Stoate
|
Mr Simon Burns | Audrey Wise
|
Mrs Eileen Gordon | |
CONTENTS
Memorandum by British American Tobacco
THE TOBACCO INDUSTRY AND THE HEALTH RISKS OF SMOKING (TB 28)
EXECUTIVE SUMMARY
Smokingour view
Co-operation with the Government
Past actions taken in response to scientific knowledge
Actions continue today
Smoking is an adult choice
The question of addiction
Environmental tobacco smoke
The role of the Government in consumer protection
THE BRITISH AMERICAN TOBACCO GROUP OF COMPANIES
UK INDUSTRY RESEARCH
Tobacco Manufacturers' Standing Committee
Harrogate
Mouse skin-painting
Results of mouse skin-painting programme
Other biological research
Nicotine research
Publication of Harrogate research
TRC Sponsored Research
BRITISH AMERICAN TOBACCO'S OWN RESEARCH
Lower biological activity cigarettes
Janus (mouse skin-painting)
Inhalation studies
The Ames test
Selective Reduction
Alternative and innovative products
Lower tar products
Funding of academic research
Scientific Research Group ("SRG")
ROTHMANS' OWN RESEARCH
1960s
Biological tests
Tar reduction
1970s
1980s
1990s
GOVERNMENT'S ROLE IN THE DEVELOPMENT OF LOWER RISK CIGARETTES
Tar/Nicotine League Tables
The Independent Scientific Committee on Smoking and Health
Tobacco substitutes
Tobacco Products Research Trust
Nicotine
The ISCSH and nicotine's role in smoking
The ISCSH and compensation
The ISCSH and product development
COMPENSATION
NICOTINE AND ADDICTION
Early scientific literature
Public health views of smoking and addiction
Nicotine's role in smoking
Product development
INGREDIENTS
Acetaldehyde and levulinic acid
Cocoa (which contains theobromine)
Liquorice (which contains glycyrrhizin)
Pyridine
Additives and children
ENVIRONMENTAL TOBACCO SMOKE
SMOKING AND YOUNG PEOPLE
ADVERTISING AND CONSUMER PROTECTION
The purpose of cigarette advertising
Advertising in a well established product category
Advertising and consumption
Advertising to market segments
Cigarette advertising and under-age smoking
Advertising and regulation
RELATIVE RISK AND AMOUNT SMOKED
Statistical studies on smoking and health
COPD
Heart disease
Public health views of moderate smoking
The role of the Government in providing information to
smokers
THE ROLE OF GOVERNMENT
Memorandum by Gallaher Group Plc
THE TOBACCO INDUSTRY AND THE HEALTH RISKS OF SMOKING (TB 8)
1.Summary
2.Foreword
3.Gallaher Group Plc
4.Smoking and Health
The collective response of the UK tobacco manufacturers
Gallaher's response
Gallaher's lower tar products
Gallaher's work to develop cigarettes containing substitute
smoking materials
Furthering the programme of tar reduction
Silk Cut
Other Research funded by the manufacturers
Smoke measurement
Compensation
Additives
Nicotine and addiction
Gallaher's approach to smoking and health
5.Public Awareness
6.Relationship with Government
Marketing activities
Under-age smoking
Trade issues, including taxation and smuggling
Environmental tobacco smoke
The way forward
7.Appendix 1The composition of a cigarette and
its smoke
The nature and composition of cigarettes
The process of cigarette design and modification
Cigarette smoke
8.Appendix 2The history of the public awareness
of the risks associated with smoking
Public awareness continued during the 1950s and 1960s
9.Appendix 3Summary of voluntary agreements and
key provisions
Memorandum by Imperial Tobacco Group PLC
THE TOBACCO INDUSTRY AND THE HEALTH RISKS OF SMOKING (TB 13)
Summary
Introduction
Scientific research into smoking and health
Imperial's product modification initiatives
Co-operation with Government
Smoking: A matter for informed adult choice
The way forward
Letter from the Corporate Affairs Director Imperial
Tobacco Group PLC (TB 13B)
Memorandum by Philip Morris Europe SA
THE TOBACCO INDUSTRY AND THE HEALTH RISKS OF SMOKING (TB19)
APPENDIX A
PHILIP MORRIS' STATEMENT OF POSITION
Memorandum by R J Reynolds Tobacco (UK) Limited
THE TOBACCO INDUSTRY AND THE HEALTH RISKS OF SMOKING (TB 31)
APPENDIX
R. J. REYNOLDS TOBACCO COMPANY: SCIENTIFIC RECORD
Examination of Witnesses
MR MARTIN
BROUGHTON, Chairman, British American
Tobacco, MR PETER
WILSON, Executive Chairman, Gallaher
Group plc, MR GARETH
DAVIS, Chief Executive, Imperial
Tobacco Group plc, MR DAVID
DAVIES, Vice President, Corporate
Affairs, Philip Morris Europe, and DR
AXEL GIETZ,
Vice President, RJ Reynolds Tobacco (UK) Limited, were examined.
Question Number
384 - 399
400 - 419
420 - 439
440 - 459
460 - 479
480 - 499
500 - 519
520 - 539
540 - 559
560 - 579
580 - 599
600 - 609
|